The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis

Published:2023-05-17 Issue:1 Volume:56 Page:181-190
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Zhou Wei,Yang Xinyue,Jin JingJing,Cheng Meijuan,Li Yajing,Bai Yaling,Xu Jinsheng^ORCID

Funder

the Hebei Major Medical Science

the project of Hebei Science and Technology Planning

Hebei province medical technology tracking project

Hebei province key research and development project

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-023-03599-w.pdf

Reference29 articles.

1. Kuang H, Huang X, Zhou Z, Cheng X, Xu G (2021) Sacubitril/valsartan in chronic kidney disease: from pharmacological mechanism to clinical application. Eur J Pharmacol 907:174288. https://doi.org/10.1016/j.ejphar.2021.174288

2. Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: a systematic analysis for the global burden of disease study 2017 (2020). Lancet (London, England) 395(10225):709–733. https://doi.org/10.1016/s0140-6736(20)30045-3

3. Li N, Lv D, Zhu X, Wei P, Gui Y, Liu S, Zhou E, Zheng M, Zhou D, Zhang L (2021) Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med 8:728089. https://doi.org/10.3389/fmed.2021.728089

4. Jankowski J, Floege J, Fliser D, Böhm M, Marx N (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11):1157–1172. https://doi.org/10.1161/circulationaha.120.050686

5. Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, Fang Y, Chen G (2020) Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. Eur J Pharmacol 884:173444. https://doi.org/10.1016/j.ejphar.2020.173444

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Heart Failure in Chronic Kidney Disease: A Review of Current Literature;Current Treatment Options in Cardiovascular Medicine;2024-07-02

2. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis;Renal Failure;2024-06-13

3. Sacubitril/valsartan alleviates sunitinib-induced cardiac fibrosis and oxidative stress via improving TXNIP/TRX system and downregulation of NF-ĸB/Wnt/β-catenin/SOX9 signaling;International Immunopharmacology;2024-05

4. An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease;Reviews in Cardiovascular Medicine;2024-04-11

5. Ist Sacubitril/Valsartan bei fortgeschrittener Nierenerkrankung und Dialysepflichtigkeit eine gute Option?;Die Nephrologie;2024-04-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3